Spero Therapeutics
SPRO
54 hedge funds and large institutions have $23.7M invested in Spero Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
8% more funds holding
Funds holding: 50 → 54 (+4)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
0.59% less ownership
Funds ownership: 26.13% → 25.54% (-0.59%)
83% less capital invested
Capital invested by funds: $143M → $23.7M (-$119M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$656K |
| 2 |
Renaissance Technologies
New York
|
+$481K |
| 3 |
SC
Shay Capital
New York
|
+$481K |
| 4 |
Man Group
London,
United Kingdom
|
+$335K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$858K |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$636K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$592K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$221K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$79.9K |
SPRO Hedge Fund Activity: Q1 2024 in Review
54 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2024, worth a combined $23.7M — down 83% from $143M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SPRO positions and 7 closed out — a net gain of 4 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $656K. The largest seller was Anson Funds Management, cutting an estimated $858K.
- 54 institutional investors held Spero Therapeutics (SPRO) as of Q1 2024, up from 50 in Q4 2023.
- Funds reported $23.7M of Spero Therapeutics stock for Q1 2024, down 83% quarter-over-quarter.
- 11 funds opened new Spero Therapeutics positions in Q1 2024 and 7 closed out, a net change of +4 holders.
- The largest Spero Therapeutics buyer in Q1 2024 was Acadian Asset Management, an estimated $656K added.
- The largest Spero Therapeutics seller in Q1 2024 was Anson Funds Management, an estimated $858K sold.
Based on aggregated 13F filings for Q1 2024.